http://orcid.org/0000-0002-9873-7507
Citations (10)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Shanlian Hu, Limin Liu, Richard F. Pollock, Johannes Pöhlmann, Depei Wu & Yabing Zhang. (2022) Intravenous iron for the treatment of iron deficiency anemia in China: a patient-level simulation model and cost-utility analysis comparing ferric derisomaltose with iron sucrose. Journal of Medical Economics 25:1, pages 561-570.
Read now
Read now
Xenophon Kassianides, Richard Bodington & Sunil Bhandari. (2021) An evaluation of ferric derisomaltose as a treatment for anemia. Expert Review of Hematology 14:1, pages 7-29.
Read now
Read now
Articles from other publishers (8)
Lu Yun, Zhu YuMei, Vallish BN, Qingu Tang & Chang Feng. (2023) The Efficacy, Safety, and Economic Outcomes of Using Ferric Derisomaltose for the Management of Iron Deficiency in China: A Rapid Health Technology Assessment. Cureus.
Crossref
Crossref
Angel Lanas, Jane M Andrews, James Lau, Murat Toruner, Susan E Bromley & Ian M Gralnek. (2022) Management of iron‐deficiency anemia following acute gastrointestinal hemorrhage: A narrative analysis and review. Journal of Gastroenterology and Hepatology 38:1, pages 23-33.
Crossref
Crossref
Antonio Ramirez de Arellano, Nicholas Norton, Dana Enkusson, Linnea Oldsberg, Yvonne Thomson, Mathias Lilja & Aysegül Aksan. (2022) Cost-Effectiveness of Intravenous Iron Formulations in Patients with Iron Deficiency Anaemia and Inflammatory Bowel Disease, in a Swedish Regional Setting Using Real-World Tender Prices. GastroHep 2022, pages 1-10.
Crossref
Crossref
R. I. Yagudina, A. Yu. Kulikov, V. G. Serpik, O. A. Gromova & I. Yu. Torshin. (2022) Pharmacoeconomic analysis of using Monofer in patients with iron deficiency anemia as part of the provision of medical care under the state guarantees program in the health care system of the Russian Federation. FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology 15:1, pages 73-86.
Crossref
Crossref
Michael Auerbach, Maureen M. Achebe, Lars L. Thomsen & Richard J. Derman. (2022) Efficacy and safety of ferric derisomaltose (FDI) compared with iron sucrose (IS) in patients with iron deficiency anemia after bariatric surgery. Obesity Surgery 32:3, pages 810-818.
Crossref
Crossref
Chuin Khai Lim, Michael Connolly & Corinne Mirkazemi. (2021) A budget impact analysis of iron polymaltose and ferric carboxymaltose infusions. International Journal of Clinical Pharmacy 44:1, pages 110-117.
Crossref
Crossref
Mustafa TEKİN, Navdar Doğuş UZUN & Fulya UZUN. (2021) Evaluation of ferric carboxymaltose treatment efficacy in women with postpartum iron deficiency anemiaDoğum sonrası demir eksikliği anemisi olan kadınlarda ferrik karboksimaltoz tedavisinin etkinliğinin değerlendirilmesi. Journal of Health Sciences and Medicine 4:1, pages 23-27.
Crossref
Crossref
Aysegül Aksan, Alain Schoepfer, Pascal Juillerat, Stephan Vavricka, Miguel Bettencourt, Antonio Ramirez de Arellano, Simona Gavata, Neige Morin, William J. Valentine & Barnaby Hunt. (2020) Iron Formulations for the Treatment of Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease: A Cost-Effectiveness Analysis in Switzerland. Advances in Therapy 38:1, pages 660-677.
Crossref
Crossref